Information Library
Managed Partnerships
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
CRO Partnerships 2010
April 12 - April 14, 2010
19th Annual Partnerships with CROs conference -
BIO International Convention 2010
May 4 - May 6, 2010
Exhibit Dates: May 4-6, 2010 Exhibitor Booth Number: 4800 Quintiles also will have a presence in the North Carolina Pavilion Quintiles Speakers: TBD -
QUINTILES AND ALLERGAN ANNOUNCE CO-PROMOTION AGREEMENT
September 25, 2009 – Quintiles Transnational Corp. and Allergan, Inc. today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR®. -
QUINTILES ANNOUNCES CLINICAL RESEARCH PARNERSHIP WITH THE UNIVERSITY OF PRETORIA
September 10, 2009 – Quintiles Prime Site Program expands into South Africa to accelerate clinical development. -
Should Venture Firms Bundle Their Biotech Portfolios?
June 29, 2009
Ron Wooten, president of NovaQuest, an investment and business-development unit of Quintiles Transnational Corp., a contract-research organization, thinks so. -
Anatomy of a Managed Partnership
May 26, 2009
Partnering affords pharma the opportunity to bolster development pipelines without taking on additional risk or adding to fixed costs. -
Drug Makers Explore Financing for Research Efforts
April 20, 2009
Several large drug makers are considering deals similar to the kind announced last year by Eli Lilly & Co. (LLY), in which the Indianapolis company will receive help from outside investors to fund clinical trials of experimental Alzheimer's disease treatments. -
Making the Most of a Smart Move
March 26, 2009
In late 2007, Scotland-based ProStrakan Group plc seemed to have everything going for it: four new European product introductions planned for an 18-month period and near-term product launches with an aggregate peak sales potential of $400 to $500 million, both backed by a 340-person pan-European salesforce. -
Grabbing a Leadership Position
March 26, 2009
Astellas-NovaQuest Alliance Establishes Market Leadership Platform for Vesicare -
Driving Near Term Sales & Savings
March 26, 2009
NovaQuest’s predecessor, PharmaBio Development, funded a dedicated sales force of 150 experienced Innovex cardiovascular representatives for two years, in return for a five-year royalty on the net sales of Advicor and its predecessor product, Niaspan®. PharmaBio also received warrants to purchase shares of Kos Pharmaceuticals stock.